Condition: Metastatic Melanoma · Head and Neck Squamous Cell Carcinoma · Sponsor: Providence Health & Services
The purpose of this study is to determine the objective response of GB1211 and pembrolizumab versus pembrolizumab and placebo in patients with advance metastatic melanoma or head and neck squamous cell carcinoma.
This description comes directly from the study's public registry record.
Chris Fountain, RN, ONC · 503-215-2691 · Christopher.Fountain@providence.org
Always discuss trial participation with your own doctor first.
| Providence Portland Medical Center | Portland, Oregon, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05913388